Seeking Alpha
View as an RSS Feed

WalkTheTalk  

View WalkTheTalk's Comments BY TICKER:
Latest  |  Highest rated
  • Biotech Weekly: 7 Stock-Specific Reasons Why You Shouldn't Buy That Speculative Biotech [View article]
    Excellent article.

    Maxim has bad reputation in investment professionals.
    Jul 30, 2015. 04:18 PM | Likes Like |Link to Comment
  • Inotek Pharmaceuticals: The Stupendous Climb Warrants Skepticism [View article]
    The possibility of their phase III will be 20% based on their fuzzy data disclosure.
    Jul 28, 2015. 06:54 PM | 1 Like Like |Link to Comment
  • Conatus: Emricasan's 4 Indications Present A Lucrative Opportunity In The Liver Disease Market [View article]
    Given how they managed trials in the past, I rank them two Pistachios out of five.

    I don't long or short this stock.
    Jul 18, 2015. 01:15 PM | 2 Likes Like |Link to Comment
  • Is Ocata Therapeutics' Lackluster Debut A Buy Or Sell? [View article]
    DWD, glad to that you can see through this pump and dump article.
    Jul 2, 2015. 11:08 AM | Likes Like |Link to Comment
  • How To Make Money In Small To Nano-Cap Biotech [View article]
    Scry, you are one of the kind. Humorous writing and interesting insight! You deserve much more respect than some so-called doctors in SA contribution.

    Let's chat about more Fugazi before the next stop.
    Jun 25, 2015. 01:41 PM | 1 Like Like |Link to Comment
  • OncoSec Medical Incorporated: The Best Immuno-Oncology Biotech You've Never Heard Of [View article]
    Goodpoint, Pingou. I am not sure if Dr. Pierce is an idiot. But I have met doctors who clouded their judgement by money, power and fame. Some of those idiots are even in Harvard medical school, UCSF, Biotech, big Pharma, and FDA, etc.

    When you look into who puppettes it behind the company like Stevie and then how Stevie stock price dropped like a rock. You know where ONCS is heading to.

    As I said, so far their clinical results are not proof of their technology in their weak clinical trial design. I will like to see more solid clinical data.

    Lets see who is silly or funny at the end. But now someone is just pumping the wrong end.
    Jun 25, 2015. 12:17 PM | Likes Like |Link to Comment
  • OncoSec Medical Incorporated: The Best Immuno-Oncology Biotech You've Never Heard Of [View article]
    Dhillion brothers who are behind ONCO are scam artists. They are good at promotion on their scam companies like Stevie and OncoMed. Please check:

    http://bit.ly/1dyZEHp

    When you read the title:"...the best immuno-Oncology company.." while their technology has been not proven in many years, not few manipulated clinical data. You know that it is a pump and dump scheme.

    Good luck, Stock (promotional) doctor!
    Jun 25, 2015. 10:42 AM | 1 Like Like |Link to Comment
  • Growing Hyaluronic Acid Market Makes Anika Therapeutics A Buy [View article]
    Kevin Sloan,

    Did you biasedly select a citation 5 years ago to support your pump thesis?

    There are much more articles to show PRP therapy better than HA in recent years.

    Please write your article a little more objectively.
    Jun 21, 2015. 03:11 PM | Likes Like |Link to Comment
  • Positioning For A Catalyst-Heavy 2015 In Achillion Pharmaceuticals [View article]
    I early expected that JNJ would have bought the company but didn't realize ACHN management sold it short for their own benefit in teenage-love-making style.

    Now their potential value is capped until they have Viagra.
    May 20, 2015. 11:54 AM | Likes Like |Link to Comment
  • Buy Arrowhead Research Corporation On The Dip [View article]
    Based on management's discussion, they more likely had very positive data from chimps. But they have to wait to release it with their other P2 clinical data. They will probably move forward with 3 and 4 mg dosage with FDA ratification. We will see these results in the next quarter hopefully.
    May 17, 2015. 01:24 PM | Likes Like |Link to Comment
  • Positioning For A Catalyst-Heavy 2015 In Achillion Pharmaceuticals [View article]
    Good debate. Steven has better evidence-based analyses. The bottom line for FDA is drug's efficacy and side effect.

    But I also appreciate SPA's chemical analyses in his article even though I disagree his point of view in the patent issue. Most of deuterated compounds have different metabolism pathway which shouldn't be much surprised. So far I haven't seen much patent issues for it.
    May 17, 2015. 01:12 PM | 3 Likes Like |Link to Comment
  • RedHill Biopharma: Undervalued Company With Huge Potential Catalyst [View article]
    Very nice brief review on their pipelines! Their published P2 data of 105 is very impressive. They have great chance to have positive results in P3.

    I am long.

    Good luck to all!
    May 5, 2015. 02:10 PM | 2 Likes Like |Link to Comment
  • Positioning For A Catalyst-Heavy 2015 In Achillion Pharmaceuticals [View article]
    CSYJ, apx. 80% of your 1267 comments are worship for GILD. Why are you are so religiously defensive for your holy GILD.

    It reminds me of cults of ISIS, not a company, in MidEast. It is kind of scary. Peace out.
    Apr 24, 2015. 07:40 PM | 2 Likes Like |Link to Comment
  • Positioning For A Catalyst-Heavy 2015 In Achillion Pharmaceuticals [View article]
    Steven, I enjoy intellectually, as always, your rigorous analyses based on scientific data.
    Apr 23, 2015. 07:37 PM | 2 Likes Like |Link to Comment
  • Celladon: CUPID-2 Is Likely To Fail [View article]
    Although I am still long, I like to give the Mr. O'Neill some credit on the issue of baseline imbalance which he showed those data in the table.

    As I mentioned before, its Cubid1 data is weak but encouraging. The results of Cubid2 can be anyone guess.
    Apr 22, 2015. 11:34 AM | 6 Likes Like |Link to Comment
COMMENTS STATS
448 Comments
276 Likes